-
Je něco špatně v tomto záznamu ?
Continuous direct compression of a commercially batch-manufactured tablet formulation with two different processing lines
J. Lyytikäinen, P. Stasiak, T. Kubelka, I. Bogaerts, A. Wanek, B. Stynen, J. Holman, J. Ketolainen, T. Ervasti, O. Korhonen
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- farmaceutická chemie * metody MeSH
- farmaceutická technologie metody MeSH
- pomocné látky * chemie MeSH
- příprava léků * metody MeSH
- tablety * MeSH
- Publikační typ
- časopisecké články MeSH
The transfer from batch-based to continuous tablet manufacturing increases the quality and efficiency of processes. Nonetheless, as in the development of a batch process, the continuous process design requires optimization studies to ensure a robust process. In this study, processing of a commercially batch-manufactured tablet product was tested with two continuous direct compression lines while keeping the original formulation composition and tablet quality requirements. Tableting runs were conducted with different values of process parameters. Changes in parameter settings were found to cause differences in tablet properties. Most of these quality properties could be controlled and maintained within the set limits effortlessly already at this stage of studies. However, the API content and content uniformity seemed to require more investigation. The observed content uniformity challenges were traced to individual tablets with a high amount of API. This was suspected to be caused by API micro-agglomerates since tablet weight variability did not explain the issue. This could be solved by adding a mill between two blenders in the process line. Overall, this case study produced promising results with both tested manufacturing lines since many tablet properties complied with the test result limits without optimization of process parameter settings.
GEA Process Engineering Wommelgem Belgium
School of Pharmacy PromisLab University of Eastern Finland Kuopio Finland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013707
- 003
- CZ-PrNML
- 005
- 20240905133351.0
- 007
- ta
- 008
- 240725e20240405ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2024.114278 $2 doi
- 035 __
- $a (PubMed)38583787
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Lyytikäinen, Jenna $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jenna.lyytikainen@uef.fi
- 245 10
- $a Continuous direct compression of a commercially batch-manufactured tablet formulation with two different processing lines / $c J. Lyytikäinen, P. Stasiak, T. Kubelka, I. Bogaerts, A. Wanek, B. Stynen, J. Holman, J. Ketolainen, T. Ervasti, O. Korhonen
- 520 9_
- $a The transfer from batch-based to continuous tablet manufacturing increases the quality and efficiency of processes. Nonetheless, as in the development of a batch process, the continuous process design requires optimization studies to ensure a robust process. In this study, processing of a commercially batch-manufactured tablet product was tested with two continuous direct compression lines while keeping the original formulation composition and tablet quality requirements. Tableting runs were conducted with different values of process parameters. Changes in parameter settings were found to cause differences in tablet properties. Most of these quality properties could be controlled and maintained within the set limits effortlessly already at this stage of studies. However, the API content and content uniformity seemed to require more investigation. The observed content uniformity challenges were traced to individual tablets with a high amount of API. This was suspected to be caused by API micro-agglomerates since tablet weight variability did not explain the issue. This could be solved by adding a mill between two blenders in the process line. Overall, this case study produced promising results with both tested manufacturing lines since many tablet properties complied with the test result limits without optimization of process parameter settings.
- 650 12
- $a tablety $7 D013607
- 650 12
- $a příprava léků $x metody $7 D004339
- 650 12
- $a farmaceutická chemie $x metody $7 D002626
- 650 12
- $a pomocné látky $x chemie $7 D005079
- 650 _2
- $a farmaceutická technologie $x metody $7 D013678
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Stasiak, Pawel $u Zentiva, Prague, Czech Republic. Electronic address: pawel.stasiak@zentiva.com
- 700 1_
- $a Kubelka, Tomáš $u Zentiva, Prague, Czech Republic. Electronic address: Tomas.Kubelka@zentiva.com
- 700 1_
- $a Bogaerts, Ivan $u GEA Process Engineering, Wommelgem, Belgium. Electronic address: Ivan.Bogaerts@gea.com
- 700 1_
- $a Wanek, Adam $u Zentiva, Prague, Czech Republic; UCT Prague, Prague, Czech Republic. Electronic address: adam.wanek@zentiva.com
- 700 1_
- $a Stynen, Bart $u GEA Process Engineering, Wommelgem, Belgium. Electronic address: Bart.Stynen@gea.com
- 700 1_
- $a Holman, James $u GEA Process Engineering, Wommelgem, Belgium. Electronic address: James.Holman@gea.com
- 700 1_
- $a Ketolainen, Jarkko $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jarkko.ketolainen@uef.fi
- 700 1_
- $a Ervasti, Tuomas $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: tuomas.ervasti@uef.fi
- 700 1_
- $a Korhonen, Ossi $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: ossi.korhonen@uef.fi
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics $x 1873-3441 $g Roč. 199 (20240405), s. 114278
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38583787 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133345 $b ABA008
- 999 __
- $a ok $b bmc $g 2143480 $s 1225573
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 199 $c - $d 114278 $e 20240405 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $a Pubmed-20240725